" “A majority of OM treatments currently being e
Post# of 72446
(Total Views: 364)
Posted On: 11/16/2017 10:18:49 AM
" “A majority of OM treatments currently being evaluated in clinical trials still target reduction in duration of OM symptoms, rather than going after OM prevention—what we’ve established as our primary efficacy outcome in the completed Phase 2 trial. We’ve set for ourselves a high bar, to be sure, but feel confident that if we deliver strong top-line results, Brilacidin-OM will stand apart from any future competition—a potential first-to-market and best-in-class OM treatment.”"
That's what he's trying to get people to understand -- prevention.
I think he's giving people a heads-up with that business about talks with prospective partners. Did you notice the "mutually beneficial LICENSING" thing? He's not going to sell Bril - he's going to do what he said, turn IPIX into a royalty company while other formulations are developed, and also, continuing research on other compounds we may have.
AND, he's letting the companies he's negotiating with know that indeed yep he's serious about talking with more than one.
AND, telling the shorts that he is NOT going to be bullied into a bad deal because they are stomping the share price.
Other than that, no reason for today's PR.
That's what he's trying to get people to understand -- prevention.
I think he's giving people a heads-up with that business about talks with prospective partners. Did you notice the "mutually beneficial LICENSING" thing? He's not going to sell Bril - he's going to do what he said, turn IPIX into a royalty company while other formulations are developed, and also, continuing research on other compounds we may have.
AND, he's letting the companies he's negotiating with know that indeed yep he's serious about talking with more than one.
AND, telling the shorts that he is NOT going to be bullied into a bad deal because they are stomping the share price.
Other than that, no reason for today's PR.
(9)
(0)